Close Menu
October 27, 2020
Sponsored by
LGC SeraCare Life Sciences

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Genome Webinar

Professor of Molecular Oncological Pathology,
University of Groningen

Consultant Clinical Scientist and Director,
Genomics Quality Assessment

Scientific Associate
Institute of Pathology, Charité – Universitätsmedizin Berlin

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

The use of circulating tumor DNA (ctDNA) as a surrogate sample type for tumor tissue is an area of significant clinical interest. ctDNA has been demonstrated to mirror the solid tumor mutational landscape and has the potential for early diagnosis of cancer as well as monitoring and tracking biomarkers associated with residual disease over time.

Despite this promise, there are still open questions regarding the best way to implement liquid biopsy approaches in the clinical setting. Our panel brings together academic, clinical, and industry experts in liquid biopsy technologies who will describe the applications of this technique and discuss its benefits and shortcomings in the context of cancer care.

Sponsored by
Sep
24

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.